1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative
    Meeting Abstract

    Arniella, M.; Ravi, A.; Stewart, C.; Freeman, S.; Awad, M.; Forde, P.; Anagnostou, V.; Henick, B.; Riess, J.; Gibbons, D.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Tired and hungry: A potential role for CD47 in T cell exhaustion
    Meeting Abstract

    Mangarin, L.; Liu, C.; Zappasodi, R.; Holland, P.; Wolchok, J.; Merghoub, T.; Weng, C. H.; Weng, C. H.; Schroder, D.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Tim-4(+) resident macrophages impair anti-tumor immunity in the serous body cavities by sequestering viable and cytotoxic CD8(+) T cells expressing high levels of phosphatidylserine
    Meeting Abstract

    Chow, A.; Schad, S.; Green, M.; Hellmann, M.; Ceglia, N.; Allaj, V.; Zago, G.; Shah, N.; Sharma, S.; Mattar, M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Characterizing double positive T cells in the tumor microenvironment: A tale of promiscuous cell fates
    Meeting Abstract

    Schad, S.; Chow, A.; Pan, H.; Mangarin, L.; Zappasodi, R.; Gigoux, M.; Redmond, D.; Hirschhorn-Cymerman, D.; Budhu, S.; Zhong, H.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Updated clinical data from the melanoma expansion cohort of an ongoing ph1/1b study of eganelisib (formerly IPI-549) in combination with nivolumab
    Meeting Abstract

    Postow, M.; Sullivan, R.; Cohen, E.; Gutierrez, M.; Hong, D.; Steuer, C.; McCarter, J.; Zizlsperger, N.; Kutok, J.; O'Connell, B.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • MHC-I skewing in mutant calreticulin-positive myeloproliferative neoplasms is countered by heteroclitic peptide cancer vaccination
    Meeting Abstract

    Gigoux, M.; Zappasodi, R.; Park, J.; Pourpe, S.; Ghosh, A.; Bozkus, C. C.; Mangarin, L.; Redmond, D.; Verma, S.; Schad, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • MK-3475-U02: Phase 1/2 study of investigational agents with or without pembrolizumab versus pembrolizumab monotherapy in melanoma
    Meeting Abstract

    Dummer, R.; Long, G. V.; Pavlick, A.; Postow, M.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J.; Tetzlaff, M.; Liao, J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Updated clinical data from the squamous cell carcinoma of the head and neck (SCCHN) expansion cohort of an ongoing Ph1/1b study of eganelisib (formerly IPI-549) in combination with nivolumab
    Meeting Abstract

    Cohen, E.; Postow, M.; Sullivan, R.; Hong, D.; Yeckes-Rodin, H.; McCarter, J.; Zizlsperger, N.; Kutok, J.; O'Connell, B.; Page, K.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Technical considerations for normalizing digital spatial profiling data with multiple within-patient samples
    Meeting Abstract

    Hether, T.; Howes, T.; Spencer, C.; Hollman, T.; Reeves, J.; Wells, D.; Friedman, C.; LaVallee, T.; Wolchok, J.; Warren, S.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • CD8 PET imaging of tumor infiltrating T cells in advanced solid tumors: A phase I first-in-human study of 89Zr-IAB22M2C, a radiolabeled anti-CD8 minibody
    Meeting Abstract

    Farwell, M.; Gamache, R.; Pandit-Taskar, N.; Postow, M.; Gordon, M.; Wilson, I.; Mascioni, A.; Wu, A.; Le, W.; Weiss, A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save